Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 4Multiple Myeloma 2Lymphoma, Non-Hodgkin 2Waldenstrom Macroglobulinemia 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Plasmacytoma 1Myelodysplastic Syndromes 1Lymphoma, Mantle-Cell 1Lymphoma, Follicular 1Lymphoma, B-Cell, Marginal Zone 1Lymphoma 1Leukemia, Myeloid, Acute 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Graft vs Host Disease 1Bronchiolitis Obliterans Syndrome 1

Interventions

Rituximab 99Cyclophosphamide 63fludarabine phosphate 54Peripheral Blood Stem Cell Transplantation 52Mycophenolic Acid 33Bortezomib 33Whole-Body Irradiation 32ibrutinib 29Dexamethasone 27Tacrolimus 25Cyclosporine 25Etoposide 22Busulfan 22Melphalan 20Filgrastim 20Methotrexate 18Lenalidomide 18Antilymphocyte Serum 18Radiotherapy 16zanubrutinib 14Bendamustine Hydrochloride 14Sirolimus 13Calcium Dobesilate 11Everolimus 10venetoclax 9ibritumomab tiuxetan 9Prednisone 9Cyclosporins 9idelalisib 8Indium 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Waldenstrom Macroglobulinemia × milatuzumab × Clear all
NCT00989586 2017-02-06

Veltuzumab and Milatuzumab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Ohio State University Comprehensive Cancer Center

Phase 1/2 Completed
35 enrolled 11 charts
Lymphoid

Lymphoma, Lymphoma, Follicular, Waldenstrom Macroglobulinemia, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡